XASX
BGT
Market cap2mUSD
Oct 09, Last price
0.01AUD
1D
0.00%
1Q
-17.65%
IPO
-93.64%
Name
Bio-Gene Technology Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bio-Gene Technology Limited, an agricultural technology firm based in Australia, focuses on the development and commercialization of insecticides and pesticides. These solutions are designed for a range of uses, encompassing animal health, crop protection, public health, and consumer applications. The company's key products include Flavocide, an insecticide utilizing beta-triketone technology, and Qcide, a natural oil derived from a specific cultivar of eucalyptus cloeziana. Bio-Gene maintains a research partnership with James Cook University to develop a tissue culture system, a critical step for expanding tree plantations and increasing future Qcide oil production. Furthermore, the company collaborates with BASF, the Grains Research and Development Corporation, and the Queensland Department of Agriculture and Fisheries to assess its products' effectiveness against grain storage pests. Established in 1995, Bio-Gene Technology Limited operates from its headquarters in Melbourne, Australia.
Key people
Soo Ding Huong
Non-Executive Chairman of the Board · since 2023
Drew Speedy
Chief Financial Officer, Company Secretary · since 2026
Tim Grogan
Chief Executive Officer, Managing Director · since 2023
Peter May
Executive Director - Research and Development · since 2018
Owen Grogan
Director · since 2023
Non-Executive Director · since 2021
Christopher Ramsay
Non-Executive Director · since 2023
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||